- Home
- BRNS vs VYNE Comparison
BRNS vs VYNE Comparison
Compare BRNS & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRNS | VYNE |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1M | 22.7M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BRNS | VYNE |
|---|---|---|
| Price | $0.63 | $0.77 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | 38.9K | ★ 535.6K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.51 | $0.29 |
| 52 Week High | $2.91 | $1.60 |
Technical Indicators
Market Signals| Indicator | BRNS | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 52.44 | 71.26 |
| Support Level | $0.65 | $0.56 |
| Resistance Level | $0.75 | N/A |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 62.94 | 86.23 |
Price Performance
Historical ComparisonAbout BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.